Metabolizing DMT – The Differences Between Oral Administration and Smoking

Research is indicating that a less efficient metabolic pathway plays a role in DMT’s psychoactivity.


Psychedelic Science Review has previously written about the biosynthesis of DMT in living organisms. Understanding this three-step process is essential in psychedelic research, particularly because some researchers hypothesize that DMT may act as a neurotransmitter.1 DMT is also of interest to psychedelic researchers because of its role in the effects of the beverage ayahuasca.

But the biosynthesis of DMT is only one side of the coin. How the body metabolizes DMT in the brain is critical to getting the complete picture of the compound’s pharmacokinetics. Although the metabolism of DMT has been extensively studied, examining what is known reveals gaps where further research can focus its efforts.

The All-Important Route of Administration

The metabolism, and therefore the effects of DMT, depend on how it enters the body and then the brain (the route of administration). People taking DMT orally experience virtually nothing. The absence of activity is due to monoamine oxidase enzymes (MAOs) in the body, which rapidly break down DMT into inactive metabolites before enough of it can reach the brain2 (another way to say DMT has low bioavailability when given orally).

However, if DMT is given orally along with a compound that inhibits MAOs, then some of it has time to pass through the digestive system and reach the brain before being metabolized. This is why ayahuasca causes effects when a person drinks it.3,4 Ayahuasca is made using other plants that contain MAO inhibitors like harmine, harmane, and harmaline.

Injecting (intravenously or intramuscularly) or smoking (vaporization and inhalation) DMT bypasses some of the first metabolism in the liver that oral administration undergoes.5 Therefore, the compound is pharmacologically active when administered via these routes.

The Mechanisms and Products of DMT Metabolism

As previously mentioned, much of DMT that is orally administered is broken down by MAOs. The two primary metabolites are: 6,7

  • DMT-N-oxide (DMT-NO)
  • Indole-3-acetic acid (IAA)

Other metabolites include: 6,8

  • N-methyltryptamine (NMT)
  • 6-hydroxy-DMT (6-OH-DMT)
  • 6-OH-DMT-N-oxide (6-OH-DMT-NO)

In the early 1980s, Barker et al. discovered that IAA resulted from the oxidative and direct deamination of DMT by MAOs.9,10 DMT-NO is produced via N-oxidation of the 2-aminoethyl group on DMT.11

Research is showing that there are other metabolic routes for the breakdown of DMT. In 2014, Gomes et al. found that DMT can also be broken down by peroxidase enzymes, resulting in other metabolites including:12

  • Hydroxy-DMT (DMT-OH)
  • N,N-dimethyl-N-formyl-kynuramine (DMFK)
  • N,N-dimethyl-kynuramine (DMK)

In terms of the mechanism at work, the authors stated that “Oxidation of DMT by peroxidases apparently uses the common peroxidase cycle involving the native enzyme, compound I and compound II.”

Different Routes = Different Mechanisms = Different Effects

Scientists are finding out that there are different metabolic pathways for the breakdown of DMT in the brain, depending on whether it is taken orally or smoked. And, not surprisingly, the data suggest that the subjective effects of DMT depend on the route of administration.

In 2015, Riba et al. observed differences in the metabolic pathways of DMT breakdown in volunteers, depending on whether it was smoked or taken orally.5 As the researchers predicted, these differences correlated with the subjective effects reported by the users.

The DMT used in the study was extracted from the root bark of the plant Mimosa tenuiflora. Isolating DMT like this for the study is essential because it removes any variables associated with the possible interactions of other compounds in the plant (the entourage effect).

The urinalysis of study participants revealed that oxidative deamination was the primary metabolic route when DMT was taken orally. These people had higher levels of IAA in their urine and no residual DMT. Specifically, IAA comprised about 97% of the compounds in the urine and DMT-NO about 3%. Notably, these subjects had no detectable DMT in their urine, demonstrating the MAO degradation pathway’s efficiency. As expected, these participants reported virtually no psychoactive effects from the oral ingestion of DMT (remember the action of MAOs in the body).

Design_Cells / Shutterstock

Participants who smoked the DMT had higher levels of DMT-NO in their urine, showing more activity in the N-oxidation metabolic pathway. The levels of IAA dropped to 63%, and DMT-NO increased to 28%. Also, unmetabolized DMT accounted for about 10% of the compounds in the urine. This residual DMT suggests that this degradation pathway is less efficient than MAO. All the participants in this group reported “fully psychoactive” effects from smoking the DMT.

The authors summarized the study findings by saying, “As the highly efficient MAO-dependent first-pass metabolism is circumvented by the smoked route, DMT metabolism is directed to the less efficient N-oxidation allowing the access of larger amounts of the parent compound to the central nervous system.”

This study had another significant finding. Analysis of the data revealed a statistically significant inverse correlation between the amount of IAA in the participant’s urine and their scores on the States of Consciousness Questionnaire (SCQ).

The SCQ uses seven subscales to assess several aspects of the mystical experience. The researchers observed the correlation between IAA levels in the urine and the Internal Unity subscale of SCQ. They explained that Internal Unity assesses “the sense of pure awareness and a merging with ultimate reality.” The inverse correlation means that the lower the IAA level in a participant’s urine, the higher their rating was for Internal Unity. The authors summarized these results by saying,

Though preliminary due to the small sample size [n=6], these results suggest that psychoactivity depends on the shift from oxidative deamination to N-oxidation.

Finding More Pieces of the DMT Puzzle

Science continues to advance the knowledge base of how and why DMT works in the brain. The effects of orally ingesting the DMT-containing brew ayahuasca, despite naturally occurring MAOs in the body, is no longer a mystery.

Now, by isolating and testing DMT in humans, the enzymatic pathways governing its metabolism and psychoactive effects are revealing themselves. Studies comparing the metabolic and subjective effects of different routes of administration of DMT offer additional insights and further reveal the complexity of nature.

Barb Bauer Headshot

Barb is the former Editor and one of the founders of Psychedelic Science Review. She is currently a contributing writer. Her goal is making accurate and concise psychedelic science research assessable so that researchers and private citizens can make informed decisions.


Notify of

1 Comment
Newest Most Voted
Inline Feedbacks
View all comments
  1. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-Dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74-88. doi:10.1016/j.brainresbull.2016.04.016
  2. McKenna DJ, Towers GHN, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and B-carboline constituents of ayahuasca. Journal of Ethnopharmacology. 1984;10:195-223. doi:10.1016/0378-8741(84)90003-5
  3. McKenna D, Callaway J, Grob C. The scientific investigation of ayahuasca. A review of past and current research. The Heffter Review of Psychedelic Research. 1998;1:65-77.
  4. Herraiz T, González D, Ancín-Azpilicueta C, Arán VJ, Guillén H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010;48(3):839-845. doi:10.1016/j.fct.2009.12.019
  5. Riba J, McIlhenny EH, Bouso JC, Barker SA. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Testing and Analysis. 2015;7(5):401-406. doi:10.1002/dta.1685
  6. Fish M, Johnson N, Horning EC. Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species. Journal of the American Chemical Society. 1955;77(22):5892-5895.
  7. Barker SA, Borjigin J, Lomnicka I, Strassman R. LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate. Biomedical Chromatography. 2013;27(12):1690-1700. doi:10.1002/bmc.2981
  8. Szára St. Dimethyltryptamine: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism. Experientia. 1956;12(11):441-442. doi:10.1007/BF02157378
  9. Barker SA, Monti JA, Christian ST. Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates. Biochemical Pharmacology. 1980;29(7):1049-1057. doi:10.1016/0006-2952(80)90169-0
  10. Barker SA, Beaton JM, Christian ST, Monti JA, Morris PE. Comparison of the brain levels of N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine following intraperitoneal injection: The IN VIVO kinetic isotope effect. Biochemical Pharmacology. 1982;31(15):2513-2516. doi:10.1016/0006-2952(82)90062-4
  11. Barker SA. N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Front Neurosci. 2018;12. doi:10.3389/fnins.2018.00536
  12. Gomes MM, Coimbra JB, Clara RO, et al. Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases. Biochemical Pharmacology. 2014;88(3):393-401. doi:10.1016/j.bcp.2014.01.035